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Exposure assessment is an integral part of health risk characterization. Exposure assessments typically address three critical aspects of exposure:
the number of people exposed to the environmental toxicant, at specific concentrations, for the time period of interest; the resulting dose; and the
relative contribution of important sources and pathways to exposure/dose. Because historically both "point-of-contact" measurements and informa-
tion about dose and related pharmacokinetic processes have been lacking, exposure assessments have had to rely on construction of "scenarios"
to estimate exposure and dose. This could change, however, as advances in development of biologic markers of exposure and dose make it possi-
ble to measure and interpret toxicant concentrations in accessible human tissues. The increasing availability of "biomarkers," coupled with improve-
ments in pharmacokinetic understanding, present opportunities to estimate ("reconstruct") exposure from measurements of dose and knowledge
of intake and uptake parameters. Human tissue monitoring, however, is not a substitute for more traditional methods of measuring exposure, but
rather a complementary approach. A combination of exposure measurements and dose measurements provides the most credible scientific basis
for exposure assessment. - Environ Health Perspect (Suppl 3):13-30 (1995)
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Introduction
People are exposed to a variety ofenviron-
mental agents, including biologic, chemi-
cal, and physical entities, in the air they
breathe, the water they drink, the food
they eat, the surfaces they contact, and the
products they use. Sometimes, exposures to
environmental toxicants are sufficient to
cause adverse health consequences, such as
birth defects, cancer, neurobehavioral
effects, and respiratory disease. The quanti-
tative estimation ofsuch health risks, based
on information about exposure and
dose-response relationships, is fundamen-
tal to policy decisions about which risks are
unacceptable and how best to manage
them (1-5).
Establishing a causal relationship
between exposures and subsequent disease
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or injury is usually difficult unless the link
is very strong, as with radon-induced lung
cancer in uranium miners. The difficulties
arise because environmentally induced
chronic disease is highly complex: multiple
exposures and causative agents, long
latency periods, and variability within and
among individuals must be considered.
The lack of appropriate data on human
exposures, doses, and related effects con-
tribute further to the difficulties encoun-
tered by risk assessors. In general, attempts
to quantify health risks resulting from
exposures to environmental agents are hin-
dered by one or both of two pervasive
problems: 1) appropriate and adequate sci-
entific data are not available; and 2) avail-
able data are difficult or impossible to
interpret because we do not have adequate
scientific understanding (6).
Realistic risk assessment depends on
accurate estimation ofboth exposures and
toxicity related to health effects. Most of
the research emphasis historically has been
on reducing uncertainties associated with
health effects (e.g., inherent toxicity,
dose-response relationship). Experience
has shown, however, that lack ofexposure
data and a defiency ofunderstanding about
important exposure mechanisms are major
sources of scientific uncertainty in most
risk assessments (2-5,7-14).
Human exposure analysis is currently
recognized as an important topic ofscientific
investigation, one that is complementary to
more traditional public health disciplines,
such as epidemiology and toxicology. The
need for exposure-related research is brought
home by the paucity ofempirical informa-
tion available to estimate exposures, and
associated doses, for most environmental
agents deemed to have public health signifi-
cance. The data on hand tend to be anecto-
dal, fragmented, uneven, and narrowly
focused on single pathways and routes
of exposure for individual chemicals
(2-5,10,11,15-20).
The purpose ofthis article is to explain
how exposure assessments are conducted in
the context of risk characterization, with
particular emphasis on the importance of
establishing the link between exposure and
associated dose. We begin with a brief
overview of the major uses of exposure
information. We next focus specifically on
the importance ofexposure evaluation for
realistic assessment of environmental
health risks, and look conceptually at how
individuals and groups who are potentially
at greater risk are identified. We summa-
rize the key concepts and definitions ger-
mane to exposure estimation, examine the
basic components ofexposure assessment,
and compare three approaches to quantita-
tive exposure estimation. The final section
provides a short discussion of the growing
importance of human tissue monitoring
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Figure 1. Important uses of human exposure information in the assessment and management of environmental
health risks (11).
for realistic assessment of exposures to
environmental agents.
Uses of Human Exposure
Information
There are four interrelated uses ofhuman
exposure data for evaluation and protection
ofenvironmental health: risk assessment,
Environmental
health
paradigm
Effects
assesment
Dose-response
assessment
What isthe
relationship
between dose
tothetarget
tissue and
adverse effects
in humans?
Hazard
identification
Isthe environ-
mental agent
capable ofcausing
an adverse effect
in humans?
risk management, status and trends analy-
sis, and epidemiology (Figure 1).
Risk assessment is a formalized process
for estimating the magnitude, likelihood,
and uncertainty of environmentally
induced health effects. Exposure assess-
ment (e.g., exposure concentrations and
related dose for specific pathways) and
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Figure 2. Relationship between an environmental health paradigm and the risk assessment framework. From
Sexton etal. l6).
effects assessment (i.e., hazard identifica-
tion, dose-response evaluation) are integral
parts ofthis process. The goal is to use the
best available information and knowledge
to estimate health risks for the subject pop-
ulation, important subgroups within the
population (e.g., children, pregnant
women, and the elderly), and individuals at
the center and "high end" ofthe exposure
distribution (1,10,11,21).
The results of risk assessment feed
directly into the risk management process
carried out by policymakers. Risk manage-
ment decisions are of four basic types:
priority setting, determination ofunaccept-
able risks, selection ofthe most cost-effec-
tive method to prevent or reduce
unacceptable risks, and evaluation of the
success ofrisk mitigation efforts. Exposure
information is crucial to each ofthese deci-
sions. In addition to data on exposures and
related health effects, decisionmakers also
must take account of the economic, engi-
neering, legal, social, and political aspects
ofthe problem (11,15).
Evaluation ofcurrent status and histori-
cal trends for exposures and doses is an
important component of both risk assess-
ment and risk management. It requires col-
lecting exposure data over a relatively long
period (e.g., 5 to 10 years), which assures
that temporal trends can be identified and
understood. Data on status and trends can
be invaluable for identifying new or emerg-
ing problems, recognizing the relative
importance ofemission sources and expo-
sure pathways, assessing the effectiveness of
pollution controls, distinguishing opportu-
nities for epidemiologic research, and pre-
dicting future changes in exposures and
effects (11,16).
Epidemiology is the study ofthe deter-
minants and distribution ofhealth status
(or health-related events) in human popu-
lations. Environmental epidemiology
examines associations between exposures to
environmental agents and associated dis-
ease or injury. It is a scientific tool that can
sometimes detect environmentally induced
health effects in populations, and it may
offer opportunities to link actual exposures
with adverse health outcomes (11,17)
Well-designed epidemiologic studies
can provide unique and powerful infor-
mation that is directly relevant to risk
assessment and to risk management deci-
sions. In addition to their other uses,
these studies can characterize the health
status of populations, describe dis-
ease occurrence through identification
ofexplanatory factors, and evaluate efforts
at disease prevention and reduction.
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But without reliable exposure informa-
tion, epidemiologic studies are much less
useful for decision making. The excess
risk for most environmentally related
health effects is small, with relative risks
and odds ratios typically less than 2.
Failure to correctly classify or quantify
exposures can introduce misclassification
error that may artificially reduce the
level of risk observed and thus limit the
usefulness ofthe study (11,17).
In addition to these four uses ofhuman
exposure information, such data also may
be essential for recognizing, diagnosing,
and treating environmentally induced ill-
ness, such as lead poisoning. Although
exposure assessments are undertaken for a
variety of reasons, the subsequent discus-
sion focuses on their use for characterizing
environmental health risks.
Exposure Assessment as a
Critical Factor in Risk
Characterization
Actions taken by society to protect its
members from the harmful consequences
ofenvironmental agents are predicated on
established or postulated links among
emission sources, human exposures, and
adverse health effects. The chain of events
depicted in Figure 2 is an "environmental
health paradigm": a simplified representa-
tion of the key steps between emission of
toxic agents into the environment and
potential disease or dysfunction in humans.
This sequential series of events serves as a
useful construct to aid in understanding
and evaluating environmental health risks
(6,11,22).
Estimation of health risks associated
with environmental agents is composed of
two primary activities: exposure assessment
and effects assessment (Figure 2). Exposure
assessment focuses on the initial portion of
the environmental health paradigm: from
sources, to environmental concentrations,
to exposure, to dose. The major goal is to
develop a qualitative and quantitative
description of the environmental agent's
contact with (exposure) and entry into
(dose) the human body. Much emphasis is
placed on estimating the magnitude, dura-
tion, and frequency ofexposures, as well as
estimating the number ofpeople exposed
to various concentrations of the agent in
question. Ideally, the relative contribution
of all important sources and pathways is
determined at the same time (1-5,21,23).
Effects assessment (Figure 2) examines
the latter portion ofthe events continuum:
from exposure, to dose, to adverse health
effects. The goals are to determine the
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Figure 3. Basic elements in the estimation and prioritization of environmental health risks (24).
intrinsic hazards associated with the agent
(hazard identification) and to quantify the
relationship between dose to the target tissue
and related harmful outcomes (dose-
response assessment). The overlap between
exposure assessment and effects assessment
reflects the importance ofthe exposure-dose
relationship to both activities (11).
Risk characterization is the last phase of
the risk assessment process. The results of
the exposure and the effects assessments are
combined to estimate the human health
risks from the anticipated exposures. For
example, a typical cancer risk characteriza-
tion would estimate both the magnitude
(e.g., 20 excess cancer cases yearly in the
United States population) and the likeli-
hood (e.g., maximally exposed person in the
population runs a risk of 1 in 1,000,000 for
developing cancer) of risks from exposures
to an environmental carcinogen.
Conceptually, as shown in Figure 3,
estimating and prioritizating health risks
are deceptively simple. Risk is a combina-
tion of effects estimates and exposure esti-
mates, where "highest" priority risks can be
thought ofas those that entail both "high"
toxicity for the agent of interest (adverse
effects are likely to occur in humans at rela-
tively low exposures or doses), and "high"
exposures for the population, subpopula-
tion, or individuals of interest (exposures
or doses are above a health-based stan-
dard). Conversely, "lowest" priority risks
involve both "low" toxicity and "low"
exposures. "Medium" priority risks are
those for which either toxicity or exposure
is "low" while the other is "high" (24).
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centraltendency
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Figure 4. Common descriptors for human exposures to environmental agents. From Sexton et al. (6).
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In practice, a variety of methods and
approaches can be used to estimate both
toxicity and exposure (Figure 3). Estimates
are more realistic the closer the surrogate is
to the event of interest (e.g., exposure),
and the more accurate the model is for
extrapolating to individuals for whom
measurements are unavailable (5,11).
Identification and
Description of Those
Potentially at Greater Risk
An important goal ofrisk assessment is to
identify and evaluate those populations,
subpopulations, and individuals at poten-
tially greater risk so that, ifwarranted,
appropriate mitigation actions can be
implemented. Conceptually, individuals
and groups are deemed to be at potentially
higher risk because they are exposed above
a health-related benchmark, or more sus-
ceptible to the effects of exposures
(6,21,25).
Measures of central tendency, such as
the median and average, along with
expressions ofvariability, like the standard
deviation, are commonly used to describe
the distribution ofexposures for a popula-
tion (Figure 4). Often, the relative posi-
tion of an individual or group in the
exposure distribution is ofprimary interest
to the exposure assessor. Among the most
frequently used descriptors for individual
and subgroup exposures are values near the
middle of the distribution; values above
the 90th percentile, which is defined by
the U.S. EPA as the "high end" ofthe dis-
tribution; and values at the extreme upper
end, such as for the most exposed person
in the population (21).
Systemic (noncancer) toxicants are usu-
ally assumed to have thresholds below
which no effects occur. Accordingly,
benchmarks to protect public health, such
as reference concentrations and doses,
ambient concentration standards, and
workplace personal exposure limits, are
often established at or below threshold lev-
els. Exposures that exceed these values,
whether they are above or below the 90th
percentile, raise concerns about potentially
elevated health risks (Figure 5A). In most
cases, however, the shape of the dose-
response curve above the benchmark is
poorly defined, making it difficult or
impossible to estimate risks quantitatively
(6,26-29).
Quantitative risk assessment for car-
cinogens is a well-established (30,31) albeit
controversial procedure. As part of the
guidelines developed by the U.S. EPA, it is
common practice to extrapolate from high
to low dose by assuming a linear, non-
threshold model for carcinogenicity. Under
this assumption, cancer risk for individuals
can be estimated directly from the exposure
or dose distribution, and the number of
excess cancer cases (i.e., the increase above
background rates) in the exposed popula-
tion can usually be estimated by multiply-
ing the average dose by both the total
number of people exposed and the
dose-response slope factor (Figure 5B).
Although individual risk is assumed to
increase with increasing exposure and dose
all along the distribution, exposures ofcon-
cern are typically defined to be those above
some de minimis level of risk (e.g., a 1 in
1,000,000 excess riskofdevelopingcancer).
A
Number of
people
B
t
Numberof
people
Individuals and groups can also be at
increased risk because they are more sus-
ceptible to the adverse effects of a given
exposure. Among the potential causes of
enhanced susceptibility are: inherent
genetic variability, age, gender, preexisting
disease (e.g., diabetes, asthma), inadequate
diet, lifestyle factors (e.g., smoking), stress,
and inadequate access to health care. To
the extent feasible, it is important to iden-
tify these susceptible individuals and
groups so that we can understand their
exposures and take account of this infor-
mation in assessing and managing risks
(1,21).
Full characterization ofhealth risks for
a particular environmental agent requires
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Figure 5. Human exposure distributions for(A) a hypothetical systemic (noncancer) toxicant and (B) a hypothetical
carcinogen (6).
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Figure 6. Mathematical expressions for some impor-
tant exposure-related and dose-related events. E, mag-
nitude of exposure; t2-t1, exposure duration; a,
availability factor; C(t), exposure concentration as a
function of time; IR, ingestion or inhalation rate; f(t),
nonlinear absorption function. From U.S. EPA(21).
consideration and description of a num-
ber offactors, which fall into three major
categories:
* population riskdescriptors, including
- number of "cases" over a specified
time,
- number (percentage) within speci-
fied range ofa health-related bench-
mark (e.g., reference dose, reference
concentration, National Ambient
Air Quality Standard);
* subgroup risk descriptors, including
- risks to more exposed subgroups,
- risks to more susceptible subgroups;
and
* individual riskdescriptors, including
- risks for individuals at the upper tail
(e.g., 90th percentile and above) of
the exposure distribution,
- risks for individuals near the center
(e.g., mean, median) ofthe exposure
distribution, and
- risks for the most exposed person in
the population (21,23,25).
In specific assessment situations, different
descriptors may be more or less appropri-
ate, depending on the ultimate uses ofthe
information and the quality and quantity
ofavailable data.
From the preceding discussion, the
importance ofexposure and dose assessment
for identifying and evaluating those who
may be at higher-than-average risk should
be obvious. Realistic estimates ofexposure
and dose are also essential to informed
decisions about whether these risks are
unacceptable, and, if so, what to do about
them. Furthermore, exposure and dose
information is a critical component of
efforts to establish whether control strategies
that have been implemented were successful
in preventing or reducing risks. It is easy to
see, then, why exposure and dose assess-
ment, in combination with effects assess-
ment, form the scientific foundation
for credible characterization, comparison,
management, and communication of
environmental health risks.
Exposure to Environmental
Agents: Concepts and
Definitions
So far, we have been using the terms
"exposure" and "dose" without explicitly
defining them. Although they are well-
established concepts familiar to all environ-
mental health scientists, their meaning
often varies depending on the context of
the discussion. It is important, however,
that these and related terms be defined pre-
cisely. In the following section we describe
and define important exposure-related
terms used in this article to be consistent
with the U.S. EPA's Exposure Assessment
Guidelines (21).
Exposure and Exposure
Concentration
Exposure is defined as contact of a bio-
logic, chemical, or physical agent with the
outer part ofthe human body, such as the
skin, mouth, or nostrils. Although there are
many instances where contact occurs with
an undiluted chemical (e.g., use ofdegreas-
ing chemicals for cleaning hands), contact
more often occurs with a carrier
medium-air, water, food, dust, or soil-
that contains dilute amounts ofthe agent.
"Exposure concentration" (e.g., mg/I,
mg/kg, pg/m3/hr) is defined as the concen-
tration of an environmental agent in the
carrier medium at the point of contact
with the body.
Exposure Estimation by Integration
and Summation
A minimal description of exposure for a
particular route must include at least two
related attributes: concentration of the
agent in the carrier medium (exposure con-
centration); and time ofcontact (duration).
Ifthe exposure concentration is integrated
over the duration ofcontact (Figure 6), the
area under the resulting curve is the magni-
tude ofthe exposure in units of concentra-
tion times time (e.g., mg/l/day, mg/kg/day,
pIg/m3/hr). This is the method ofchoice to
describe and estimate short-term exposures,
where integration times are on the order of
minutes, hours, or days.
Over periods of months, years, or
decades, exposures to most environmental
agents occur intermittently rather than
continuously. Yet long-term health effects,
such as cancer, are customarily evaluated
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Figure 7.The relationship among data collection, predictive models, and exposure and dose estimates.
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based on an average dose over the period of
interest (typically years), rather than as a
series of intermittent exposures. Conse-
quently, long-term doses are usually esti-
mated by summing doses across discrete
exposure episodes and then calculating an
average dose for the period ofinterest (e.g.,
year, lifetime). Although the integration
approach can also be used to estimate long-
term exposures or doses, its application to
time periods longer than about a week is
usually difficult and inconvenient.
Exposure Measurements and Models
Direct measurements are the only way to
establish unequivocally whether and to
what extent individuals are exposed to
specific environmental agents. But it is nei-
ther affordable nor technically feasible to
measure exposures for everyone in all pop-
ulations of interest. Models, which are
mathematical abstractions ofphysical real-
ity, may obviate the need for such extensive
monitoring programs by providing esti-
mates ofpopulation exposures (and doses)
that are based on a smaller number ofrep-
resentative measurements (Figure 7). The
challenge is to develop appropriate and
robust models that allow for extrapolation
from relatively few measurements to esti-
mates of exposures and doses for a much
larger population (2-5,21).
For relatively small groups, measure-
ments or estimates can be made for some
or all of the individuals separately, and
then combined as necessary to estimate the
exposure (or dose) distribution. For larger
groups, exposure models and statistics can
sometimes be used to derive an estimate of
the distribution ofpopulation exposures,
depending on the quantity and quality of
existing data. Monte Carlo and other sta-
tistical techniques are increasingly being
used to generate and analyze exposure
distributions for large groups (21,32).
Exposure in the Context ofan
Environmental Health Paradigm
An expanded and more detailed version of
the environmental health paradigm pre-
sented in Figure 2 is depicted in Figure 8.
It shows the domain of exposure assess-
ment, which includes important events,
mechanisms, and processes that provide a
context for understanding and estimating
exposures and doses for environmental
agents.
The release of an agent into the envi-
ronment, its ensuing transport, transfor-
mation, and fate in various environmental
media, and its ultimate contact with peo-
ple are critical events in understanding
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Figure 8. The domain of exposure assessment in relation to an environmental health paradigm.
how and why exposures occur. Definitions
for key events in the continuum are
summarized below (21).
Emission Source. The point or area of
origin for an environmental agent is
known as a "source." Agents are released
into the environment from a wide variety
ofsources, which are often categorized as
point sources (e.g., incinerator) versus area
sources (e.g., urban runoff), stationary
sources (e.g., refinery) versus mobile
sources (e.g., automobile), and anthro-
pogenic sources (e.g., landfill) versus
nonanthropogenic sources (e.g., natural
vegetation).
Exposure Pathway. An exposure path-
way is the physical course taken by an
agent as it moves from a source to a point
ofcontactwith a person.
Exposure Concentration. Exposure
concentration is the concentration of an
agent in a carrier medium at the point of
contact with the outer boundary of the
humanbody.
Most exposure assessments do not stop
at exposure concentration, since that infor-
mation alone is not very useful unless it is
converted to dose or risk. Assessments
therefore usually estimate how much of an
agent is expected to enter the body. This
transfer of an environmental agent from
the exterior to the interior ofthe body can
occur by either or both of two basic
processes: intake anduptake.
Intake. Intake is associated with inges-
tion and inhalation. The agent, which is
likely to be part of a carrier medium (e.g.,
air, water, food), enters the body by bulk
transport, usually through the nose or
mouth. The rates ofbulk transport into the
body are assumed to be the same for both
the agent and the carrier medium. The
amount of the agent that crosses the
boundary per unit time can be referred to
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as the "intake rate," which is the product of
the exposure concentration times the rate
ofeither ingestion or inhalation.
Uptake. Uptake is associated with the
dermal route of exposure, as well as with
ingestion and inhalation after intake has
occurred. The agent, as with intake, is
likely to be part ofa carrier medium (e.g.,
water, soil, consumer product), but enters
the body by crossing an absorption barrier,
such as the skin, respiratory tract, or gas-
trointestinal tract. The rates ofbulk trans-
port across the absorption barriers are
generally not the same for the agent and
the carrier medium. The amount of the
agent that crosses the barrier per unit time
can be referred to as the "uptake rate".
This rate is a function ofthe exposure con-
centration, as well as of the permeability
and surface area of the exposed barrier.
The uptake rate is also called a "flux".
Dose. Once the agent enters the body
by either intake or uptake, it is described as
a "dose." Several different types ofdose are
relevant to exposure estimation.
Potential (Administered) Dose.
Potential, or administered dose, is the
amount of the agent that is actually
ingested, inhaled, or applied to the skin.
The concept ofpotential dose is straight-
forward for inhalation and ingestion,
where it is analogous to the dose adminis-
tered in a dose-response experiment. For
the dermal route, however, it is important
to keep in mind that potential (or adminis-
tered) dose refers to the amount of the
agent, whether in pure form or as part ofa
carrier medium, that is applied to the surface
of the skin. In cases where the agent is in
diluted form as part ofa carrier medium,
not all ofthe potential dose will actually be
touching the skin.
Applied Dose. Applied dose is the
amount of the agent directly in contact
with the body's absorption barriers, such as
the skin, respiratory tract, and gastroin-
testinal tract, and therefore available for
absorption. Information is rarely available
on applied dose, so it is calculated from
potential dose based on factors such as
bioavailability (Figure 6).
Internal (Absorbed) Dose. The amount
of the agent absorbed, and therefore avail-
able to undergo metabolism, transport,
storage, or elimination, is referred to as the
"internal" or "absorbed dose" (Figure 6).
Delivered Dose (Body Burden). The
portion ofthe internal (absorbed) dose that
reaches a tissue of interest is called the
"delivered dose."
Biologically Effective (Target) Dose.
The portion of the delivered dose that
reaches the site or sites of toxic action is
called the "biologically effective dose."
The link, if any, between biologically
effective dose and subsequent disease or ill-
ness depends on the relationship between
dose and response (e.g., shape of the
dose-response curve), underlying pharma-
codynamic mechanisms (e.g., compensa-
tion, damage, repair), and important
susceptibility factors (e.g., health status,
nutrition, stress, genetic predisposition).
Biologic Effect. A measurable response
to dose in a molecule, cell, or tissue is
termed a "biologic effect." The significance
ofa biologic effect, whether it is an indica-
tor or a precursor for subsequent adverse
health effects, may not be known.
Adverse Effect. A biologic effect that
causes dysfunction, injury, illness, or death
is defined as an "adverse health effect."
Linking Exposure Events and
Dose Events
The schematic framework in Figure 9
shows how the interrelationships among
significant exposure- and dose-related
events in the paradigm can be conceived.
The example assumes that perfect informa-
tion on exposure and dose is available for a
hypothetical population exposed to a single
agent by multiple pathways and routes.
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Figure 9. The relationship among important exposure-related and dose-related events in the context of exposure assessment.
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It illustrates the route-specific nature of
both exposure and dose for the environ-
mental agent prior to its absorption into
the body (uptake), and the integration ofit
across all routes that occurs subsequent
to uptake.
It is important to keep in mind that,
although events along the continuum are
correlated, the relative position ofa partic-
ular individual within a distribution may
change dramatically from one event to the
next. It is not the case, for example, that
the person with the highest (or lowest)
exposure will necessarily have the highest
(or lowest) dose, and vice versa. Moreover,
the distribution itself may be altered (e.g.,
an increase or decrease in variance) as the
agent or its metabolite/derivative moves
through the various stages from exposure
concentration to biologically effective dose.
To make realistic estimates for a spe-
cific event (e.g., an internal dose), it is nec-
essary to have at least one oftwo types of
information: measurements of the event
itself(e.g., internal dose); or measurements
of an earlier (e.g., potential dose) or later
(e.g., delivered dose) event in the contin-
uum. It is also necessary to understand the
critical intervening mechanisms and
processes (e.g., pharmacokinetics) that gov-
ern the relationship between the event
measured and the event of interest (e.g.,
internal dose). Unless such data are on
hand, extrapolating from one event to
another, moving from either exposure to
dose (from left to right in Figure 9) or
from dose to exposure (from right to left in
Figure 9), is problematic.
Suitable data and adequate understand-
ing are seldom, ifever, available to describe
and estimate all ofthe significant events for
the groups and individuals of interest.
Generally speaking, measurement ofexpo-
sure concentration and delivered dose
(body burden) is relatively straightforward,
while measurement ofpotential (adminis-
tered) dose and internal (absorbed) dose is
usually possible only with substantially
greater effort. Measurement ofbiologically
effective (target) dose is also possible in
some cases. However, it is typically difficult
or impossible, given existing approaches
and methods, to measure applied dose.
This situation presents us with a
conundrum. We would like to have realis-
tic estimates ofexposure concentrations of
an agent for all important pathways, and
the resulting biologically effective dose.
Typically, however, if relevant data are
available at all, they are related to exposure
concentrations for one pathway or route of
exposure. In the few cases where data on
dose are also available, these data usually
reflect delivered dose (body burden) rather
than biologically effective dose. Even if
suitable measurements of both exposure
concentration and delivered or target dose
are on hand, the absence ofpharmacoki-
netic understanding to relate these mea-
surements to each other, as well as to other
significant events along the continuum,
seriously impairs efforts to establish the
link between exposure and dose.
We are thus leftwith asituation inwhich
we can measure specific events on either side
ofthe body's absorption boundaries; but we
can relate them to each other onlyby usinga
series of unsubstantiated, even heroic,
assumptions. Yet it is precisely this relation-
ship between exposure and dose that is
critical torealistic riskcharacterization.
Basics of Exposure
Assessment
Assessing human exposure to an environ-
mental agent involves the qualitative
description and the quantitative estimation
ofthe agent's contact with (exposure) and
entry into (dose) the body. Although no
two exposure assessments are exactly the
same, most assessments address three key
areas that are important for risk assessment
and for risk management decisions: the
number ofpeople exposed at specific con-
centrations for the time period ofinterest;
the resulting dose; and the contribution of
important sources and pathways to expo-
sure or dose. A list ofthe types ofestimates
that might comprise a comprehensive
exposure assessment might include the
following (21,33):
Exposure
* routes and durations ofinterest;
* distribution (e.g., mean, variance, 90th
percentile)-population, important
subpopulations (e.g., more exposed,
more susceptible);
* individuals-average, upper tail of
distribution, mostexposed inpopulation;
Dose
* linkwith exposure;
* distribution (e.g., mean, variance, 90th
percentile)-population, important
subpopulations (e.g., higher doses,
more susceptible);
* individuals- average, upper tail of
distribution, highestdose inpopulation;
Causes
* relative contribution of important
sources;
* relative contribution of important
environmental media;
relative contribution of important
exposure pathways;
* relative contribution of important
routes ofexposure;
Variability
* within individuals (e.g., changes in
exposure from day-to-day for the same
person);
* between individuals (e.g., differences in
exposure on the same day for two
different people);
* between groups (e.g., different socio-
economic classes or residential
locations);
* over time (e.g., changes in exposure/dose
from oneyear to the next);
* across space (e.g., changes in expo-
sure/dose from one region of the
country to another)
Uncertainty
* lack of data-statistical error in mea-
surements, model parameters, etc.;
misidentification ofhazards and causal
pathways;
* lack of understanding-mistakes in
functional form of models, misuse of
proxy data from analogous contexts.
The first step in any exposure assess-
ment must be to determine which data are
necessary; the next step must be to specify
how to obtain them. These steps can be
accomplished by addressing a series of
questions about the assessment's purpose,
scope, level of detail, and approach
(21,23).
Purpose
Will the assessment:
* support regulations for specific
emission sources?
* set standards for specific environmental
media?
* determine the need to remediate a waste
site or chemical spill?
* enable us to set priorities?
* determine whether an agent should be
introduced into commerce?
Scope
* Which agent or mixture ofagents will
be evaluated?
* Will the assessment be site-specific,
local, regional, or national?
* Which sources, pathways, media,
routes, and populations are important?
LevelofDetail
* What level ofdetail and degree of con-
fidence are adequate to achieve the
purpose ofthe assessment?
* Will resource limitations limit the
depth, breadth, and utility ofthe effort?
* What level of detail is needed about
linkages among sources, exposures,
doses, effects and risks?
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Approach
* Is measuring exposures, constructing a
scenario, or reconstructing internal
dose the most appropriate way to
estimate exposures?
* What measurements, methods, and/or
models are available to provide the
needed information?
* Howwill critical data needs and gaps in
knowledge be addressed?
Answers to these questions provide a
context, at the outset, for identifying viable
options and then for deciding how best to
conduct the necessary exposure assessment.
ThreeApproaches to
Quantitative Exposure Assessment
Quantitative estimation of exposure is
often the central feature of assessment
activities. The quantitative estimation of
exposure can be approached in three gen-
eral ways: point-of-contact measurements,
construction ofa scenario, and reconstruc-
tion ofinternal dose to calculate associated
exposures (21,23).
Point-of-contact Measurements.
Measurement of actual exposure as it
occurs (i.e., exposure concentration and
duration) at the point of contact with the
human body.
Scenario Evaluation. Estimation of
exposure by use of a hypothetical but
plausible scenario to analyze exposure
concentration and time ofcontact.
Exposure Reconstrction. Estimation of
exposure from dose, based on reconstruc-
tion of internal dose from human tissue
measurements and knowledge ofpharma-
cokinetics, and data or assumptions about
intake and uptake rates.
These three generic approaches to
quantitative estimation of exposure are
independent and complementary. Each
relies on different kinds of data and has
different strengths and weaknesses. It is
potentially useful, therefore, to employ
multiple approaches as a way of checking
the robustness ofresults. Among other fac-
tors, the choice ofwhich method to use
will depend on the purpose ofthe assess-
ment and the availability of suitable
methods, measurements, and models (21).
Point-of-contact Measurement
Point-of-contact measurements quantify
exposure as it occurs by measuring the con-
centration of the agent at the interface
between the person and the environmental
(carrier) medium. Radiation dosimeters,
such as those worn on the lapel oflabora-
tory technicians, are perhaps the best-
known example. These small badges
measure radiation exposure as it occurs,
providing an integrated measurement over
a specified period. Other examples include
small, personal monitors for carbon
monoxide, particles, and volatile organic
chemicals such as those used in EPA's
Total Exposure Assessment Methodology
(TEAM) studies (14,21,34). Examples of
point-of-contact measurements and their
relevance to exposure assessment are
provided in Table 1.
The major strength ofthis approach is
that it measures exposure directly for the
monitoring period. Typically, however,
this period is relatively short (e.g., minutes,
hours, days), thereby limiting the useful-
ness of this approach for estimating
lifetime exposure. Furthermore, point-of-
contact measurements are costly and time
Table 1. Examples of "point-of-contact" measurements used in exposureassessments.!
Typical information needed
Type of measurement Element estimated Examples to characterize exposure
Airpump/particulates Exposure ofan individual TEAM study All ofthese methods directly
and vapors orpopulation via the air measure individual exposure dur-
ing time sampled. To characterize
exposure to population,
Passive vaporsampling Exposure of an individual TEAM study relationships between individuals
orpopulation via the air and the population must be
medium established as well as rela-
Split sample offood Exposures of an individual TEAM study tionships between times sampled
and drinking water orpopulation via ingestion and othertimesforthe same
Skin patch samples Dermal exposure of an Pesticide individuals, and relationships
individual or population applicator study between sampled individuals and
other populations. To make these
links, activities ofthe sampled
individuals compared to popula-
tions characterized should be
described in some detail.
TEAM, total exposure assessment methodology. Taken from U.S. EPAguidelines (21).
consuming, can be burdensome for the
participants, and are often constrained by a
lack ofsuitable methods (14,21,34).
Scenario Construction
When direct measurements are not avail-
able for the population of interest, a sce-
nario approach is frequently used to
estimate exposures and doses. The expo-
sure assessor uses the available facts (e.g.,
databases, models), in combination with
assumptions, inferences, and professional
judgment, to construct a plausible set of
assumptions (i.e., a scenario) that describes
quantitatively how contact occurs between
people and environmental agents.
A typical scenario estimates exposure by
merging two separate but essential compo-
nents of exposure: concentration of the
agent in the environmental (carrier)
medium, estimated by using data or making
assumptions about source-pathway- expo-
sure interactions; and contact time with
people, estimated by using existing data and
knowledge, or by making reasonable
assumptions about time-activity patterns,
lifestyle characteristics, residential proximity
to sources, and other factors. The doses
related to exposure are estimated using
knowledge and assumptions about relevant
pharmacokinetic processes. Examples ofthe
types ofmeasurements useful in construct-
ing a scenario and their relevance to expo-
sure assessments are provided in Table 2.
Both the "microenvironmental" (3,21,34)
and pathway-exposure factors ("PEF")
methods for exposure estimation (19) are
variations ofthe scenario approach.
The primary advantage ofthe scenario
approach is that it enables assessors to
make estimates ofexposure and dose with
very limited data. On the other hand, the
uncertainty introduced by the need to
make assumptions and inferences in the
face oflimited information is also its major
disadvantage. The scenario approach is
most useful when the assessor has some
insight into the completeness, soundness,
validity, and uncertainty associated with
the underlying assumptions and inferences,
and understands their overall effect on the
uncertainty of the estimated values for
exposure and/or dose (21,23).
Reconstructive ExposureAssessment
The third approach uses dose information
to estimate exposure. If measurements
(e.g., body burden, elimination levels) are
available to "reconstruct" internal dose,
past exposures can be calculated by incor-
porating information or assumptions about
rates of intake and uptake. Appropriate
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application of this approach depends on
the availability of measurements of bio-
markers in human tissue so that internal
dose can be realistically reconstructed
(calculated), and adequate information to
accurately estimate intake, uptake, and
metabolic rates. Examples of the types of
biomarkers measured in human tissue that
can be used for reconstructing internal
dose and their relevance to exposure assess-
ment are given in Table 3.
The strength of the reconstructive
approach is that it can demonstrate
unequivocally that exposure and uptake
have occurred. However, because internal
dose is integrated across all routes ofexpo-
sure, the method does not usually provide
information about the relative importance
of inhalation, ingestion, and dermal
absorption. Perhaps the most serious prob-
lem with implementing this approach is
Table 2. Examples oftypes of measurements useful in construction of scenarios for exposure assessments.a
Typical information needed to characterize
Type of measurement Element estimated Examples exposure
Fixed-location monitoring
Short-term media monitoring
Source emissions monitoring
Environmental medium; samples used to
establish long-term indications of media
quality and trends
Environmental orambient medium; samples
used to establish a snapshot ofquality of
medium over relatively shorttime
Release rates tothe environment from
sources; often given in terms of relation-
ships between release amounts and
various operating parameters ofthe
facilities
National Stream QualityAccounting
Network(NASQAN), waterquality net-
works, air quality networks.
Special studies of environmental media,
indoor air
Stack sampling, effluent sampling, leachate
sampling from landfills, incinerator ash
sampling, fugitive emissions sampling,
pollution control device sampling
Population location and activities relative to
monitoring locations; fate of pollutants over
distance between monitoring and point of
exposure; timevariation of pollutantconcen-
tration at point of exposure
Population location and activities(this is
critical since itmustbecloselymatchedto
variations inconcentrations duetoshortperiod
ofstudy);fateofpollutants between measure-
mentpointand pointofexposure; time
variation ofpollutantconcentration atpointof
exposure
Fate of pollutants from part of entry into the
environment to point of exposure; popula-
tion location and activities; time variation
of release
Food samples
Concentrations of contaminants in food
supply
U. S. Food and Drug Administration Total
DietStudy, marketbasket studies, shelf
studies, cooked-food sampling
Dietary habits ofvarious age, sex, or
cultural groups; relationship between food
items sampled and groups (geographic,
ethnic, demographic) studied; relationships
between concentrations in uncooked versus
prepared food
Drinking water samples
Consumer products samples
Breathing zone measurements
Micro-environmental studies
Surface soil samples
Soil core
Fish tissue samples
aTaken from U. S. EPAguidleines (21).
Concentrations of pollutants in drinking
water supply
Concentration levels ofthe products
Exposure to airborne chemicals
Ambient medium in a defined area, e.g.,
kitchen, automobile interior, office setting,
parking lot
Degree of contamination of soil available
for contact
Soil including pollution available forground-
watercontamination; can be an indication of
qualityandtrends overtime
Extent of contamination of edible fish
tissue
Ground WaterSupplySurvey, Community
WaterSupply Survey, tap water samples
Shelfsurveys, e.g., solventconcentration in
household cleaners
Industrial hygiene studies, occupational
surveys, indoorair studies
Special studies of indoorair, house dust,
contaminated surfaces, radon measure-
ments, office building studies
Soil samples at contaminated sites
Soil samples at hazardous waste sites
National Shellfish Survey
Fate and distribution ofpollutants from
point of sample to point ofsample to point
ofconsumption; population served by
specific facilities and consumption rates; for
exposure dueto other uses (e.g., cooking,
showering), need to knowactivity patterns
and volatilization rates
Establish use patterns and marketshare of
particular products, individual exposure at
various usage levels, extent of passive
exposure
Location, activities, and time spent relative
to monitoring locations; protective mea-
sures/avoidance
Activities ofstudy populations relative to
monitoring locations and time exposed
Fate of pollution on or in soil; activities of
potentially exposed populations
Fate of substance in soil; speciation and
bioavailability, contact and ingestion rates
as a function ofactivity patterns and age
Relationship ofsamples to food supply of
individuals or population of interest;
consumption habits; preparation habits
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Table 3. Examples of human tissue measurements used in exposure assessments.
Typical information needed
Type of measurement Element estimated Examples to characterize exposure
Breath Total internal dose for individuals or popula- Measurement ofvolatile organic chemicals Relationship between individuals and popula-
tion (usually indicative of relatively recent (VOCs), alcohol. (usually limited to volatile tion; exposure history (i.e., steady-state or not)
exposures) compounds) pharmacokinetics (e.g., chemical half-life),
possible storage reservoirs within the body;
Relationship between breath content and body
burden
Blood Total internal dose for individuals or popula- Lead studies, pesticides, heavy metals (usually Same as for breath, plus relationship
tion (may be indicative of either relatively bestfor soluble compounds, although blood between blood content and body burden
recent exposures to fat-soluble organics or lipid analysis may reveal lipophilic compounds)
long-term body burden for metals)
Adipose tissue Total internal dose for individuals or population National Human Adipose Tissue Survey- Same as for breath, plus relationship
(usually indicative of past exposure in weeks to dioxin and PCB studies (usually limited to between adipose content and body burden
months range; can sometimes be used to lipophilic compounds)
evaluate exposure patterns)
Nails, hair Total internal dose for individuals or popula- Heavy metal studies (usually limited to metals) Same as for breath, plus relationship
tion (usually indicative of long-term averages between nails, hair content and body burden
forfat soluble organics)
Urine Total internal doseforindividuals orpopulation Studies oftetrachloroethylene and Same as for breath, plus relationship
(usually indicative ofelimination rates); timefrom trichloroethylene between urine content and body burden
exposure toappearance in urine mayvary,
depending on chemical
Taken from U.S. EPA guidelines (21).
the lack ofphysiologically based pharmaco-
kinetic models for the environmental
agents of interest. Without a good under-
standing of pharmacokinetics, including
bioavailability, absorption, disposition,
metabolism, and elimination, reconstruct-
ing internal dose and calculating previous
exposures are highly uncertain (21,23).
Role of Human Tissue
Monitoring in Exposure
Assessment
The vast majority of quantitative risk
assessments conducted by the U.S. EPA
have dealt with lifetime cancer risks from
long-term exposures to low levels ofsingle
chemicals via one pathway or route. In the
face ofa serious lack ofdata on both cancer
potency and lifetime exposures in humans,
an elaborate set of guidelines has been
developed for cancer risk assessment
(30,31). The guidelines provide assessors
with formal guidance on how and when to
apply a variety of "default" assumptions to
estimate carcinogenic risk. For example, in
the absence ofevidence to the contrary, it
is common to assume that a high dose ofa
carcinogen received over a short time is
equivalent to a corresponding low dose
spread over a lifetime.
Most cancer risk assessments have been
done by constructing scenarios because there
is an absence ofadequate and appropriate
data; because there is a lack ofscientific
understanding to interpret available data. Of
necessity, these scenarios have incorporated
default assumptions to estimate exposure
and dose. The scenario approach is based on
a logical, stepwise analysis ofthe important
events in the environmental health paradigm
(Figures 8,9), from source, through path-
ways, to exposure, and ultimately to biologi-
cally effective dose. Important parameters
(e.g., emission rates, product-use patterns,
transport and fate processes, concentrations
in food and water, human consumption pat-
terns, uptake rates, metabolism, excretion)
KEY
] Targettissue
O Media forbiological monitoring
Figure 10. Simplified diagram of exposure routes, uptake sites, target tissue, and potential tissue and excreta for
biological monitoring (40).
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are either estimated from available data or
assumed to be represented adequately by
defaultvalues.
Because information is lacking, scenar-
ios do not usually include a complete
description ofthe exposure and dose distri-
bution for the population of interest.
Instead, scenarios emphasize estimating
several points on the population distribu-
tion oflifetime individual exposures (or
doses) (Figures 4,5B). Historically, three of
these points have been: average exposure
(dose), which is related to the total number
ofexcess cancer cases expected in the popu-
lation from the anticipated exposures;
exposure (dose) for an individual in the
upper tail ofthe distribution; and exposure
(dose) for the most exposed individual in
the distribution. Although scenarios have
obvious limitations, such as lack of data,
unvalidated default assumptions, and point
estimates of exposure or dose, that con-
tribute significantly to uncertainties in risk
assessment, they remain the only viable
method to estimate exposure or dose in the
absence ofdirect measurements.
Historically, human tissue measure-
ments have played a relatively small role in
most exposure assessments because of the
nature ofthe risks being assessed (e.g., life-
time cancer risk related to "average" life-
time exposure or dose), the types of
questions being asked (e.g., what incre-
mental risks are associated with a single
source/pathway/route), the lack ofappro-
priate human tissue data (e.g., no data for
the population/situation ofinterest), and
our still largely deficient understanding of
pharmacokinetics (e.g., we cannot yet
interpret human tissue measurements in
terms ofexposure).
Biologic Markers (Biomarkers) of
Exposure
Many of the dose-related and health-
related events in the environmental health
Table 4. Examples of biomarkers forsignificant events in the environmental health paradigm.'
Exposure biomarkers Marker Exposure Biologic media
Delivered dose markers Cotinine Nicotine in cigarette smoke Bodyfluids
Lead Lead in environment Bodyfluids and tissues
(hair, nails, teeth)
DDE DDT Adipose tissue
Aflatoxin Aflatoxin in food stuff Bodyfluids
Mutagenesis Chemical mutagens Bodyfluids
Biological effective
dose markers DNAadducts Benzo[alpyrene WBC
Protein adducts Ethylene oxide RBC
(hemoglobin)
Biologic effects
(response) markers Chromosomal
Aberrations Mutagenic chemicals WBC
Sisterchromatid exchange WBC
Micronuclei Epithelia
Point Mutations
HGPRT Mutagenic chemicals WBC
Thymidine-kinase WBC
Oncogne activation Chemical carcinogens Tissue
(benzo[alpyrene)
Elevated protoporphyrin Lead RBC
Decreased acetylcholin- Organic phosphate pesticides Plasma
esterase
Effects biomarkers Marker Disease
Adverse effects Altered gene expression Liver cancer
(subclinical disease) markers Serum alpha-fetoprotein GI disease
Fetal neuraltubedefect
Carcinoembryonic antigen GI cancers
OtherGI diseases
Tumor-specific antigens Various cancers
SGOT Myocardial infarction
abbreviations: DDE, dichlorodiphenyldichloraethylene; DDT, dichlorodiphenyetrichloroethane; WBC, white blood
cell; RBC, red blood cell; HGPRT, hypoxanthine-guanine phosphoribosyl transferase; SGOT, serum glutamic-
oxaloacetic transambinase; GI, gastrointestinal.' From(40).
paradigm (Figures 8,9) occur at inaccessi-
ble sites in the body (e.g., liver, developing
organs). Biologic markers (biomarkers)
are indicators ofthese significant but inac-
cessible events that can be measured in
accessible human tissues (e.g., blood)
(Figure 10). Biomarkers fall into several
categories, including the following:
* Unchanged exogenous agents-sol-
vents, asbestos fibers, PCBs, ethanol,
nicotine, and heavy metals;
* Metabolized exogenous agents (precur-
sors in parentheses)-phenol (benzene),
DDE (DDT), cotinine (nicotine) BPDE,
I (benzo[a]pyrene), retinol (5-carotene),
acrolein (cyclophosphamide);
* Endogenously produced molecules
(exposure/disease in parentheses)-
exposure markers, e.g., acetyl cholines-
terase (organic phosphate pesticides),
y-glutamyltransferase (liver toxins),
porphyrin ratios (lead and other met-
als); and disease markers, e.g., alpha-
fetoprotein (liver cancer), SGOT
(myocardial infarction), and creatine
kinase (muscle trauma);
* Molecular changes (exposure in paren-
theses)-glycosylated hemoglobin
(dietary glucose), DNA adducts (chem-
ical carcinogens), protein adducts (elec-
trophilic chemicals), chromosome
aberrations (clastogens), alkylated
amino acids (electrophilic chemicals),
and micronuclei (clastogens); and
* Cellular/tissue changes (in response to
various toxins)-cell histology, lym-
phocyte ratios, sperm mobility, sperm
counts, macrophage activity, and red
blood cell counts
and they can be obtained from many
human tissues and excreta by invasive and
nonivasive methods. (Noninvasive means
that sample collection does not require pen-
etration ofthe body envelope. A complete
definition ofinvasive/noninvasive must also
include consideration ofsocial, cultural,
and pyschological factors.) Invasive meth-
ods may involve expired air, saliva, semen,
urine, sputum, hair, feces, breast milk, or
fingernails. Nonivasive methods may yield
samples from blood, lung tissue, bone mar-
row, amniotic fluid, liver tissue, bone, fol-
licular fluid, adipose tissue, or bloodvessels.
The expanding availability ofbiomarkers
for events of interest in the environmental
health paradigm (Tables 4,5) offers increas-
ing potential to use them in exposure
estimation (2-5,35-44).
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Table 5. Examples ofconfirmed or postulated biomarkersfor significant events in the environmental health paradigm.a
Biologically effective Early biological Altered structure or
Exposure Delivered dose dose effect function Clinical disease Prognostic significance
Lead Blood lead levels Lead level in bone Inhibition of Accumulation ofZn Anemia Rate of lead decrease
marrow cells d-aminolevulinic protoporphyrin on removal from exposure
acid dehydratase
Ethylene dioxide Hemoglobin adducts DNA adducts HPRT mutationC Sisterchromatid Leukemia ?
exchange
Benzidine Urinary benzidine DNA adducts Activated H-rasoncogene DNA hyperploidy Bladdercancer GAGd
Ionizing radiation Inhaled radionuclides HPRT mutation Chromosomal micronuclei Hyperplasia Lung cancer Tumorantigens
Dioxin TCDDe in blood Urinary porphyrins Hyperkeratinization of ? Chloracne ?
sebaceous gland
Fatty food Serum cholesterol HDL/LDL' Chylomicrons in blood Serum enzymes Myocardial Serum enzymes
infarction
Dibromochloro- DBCP in blood ? Mean plasma FSH9 Sperm count Oligospermia Sperm motility
propane
'The order ofspecific components in each continuum may be speculative and subject to other interpretation. bThis component can be represented by markers butalso be rep-
resented by a constellation of signs and symptoms. CHPRT, hypoxanthinequanine phosphoribosyl transferase. dGAG glycosaminoglycans. °TCDD, 2,3,7,8,-tetrachlordibenzo-
p-dioxin. fHDL/LDL, high density lipoprotein/low density lipoprotein. 9FSH, follicle stimulating hormone. From Schulte (44).
Interpreting Biomarkers for
Exposure Assessment
Biologic markers can provide unequivocal
evidence that exposures and uptake have
occurred, and we may be able to use them
as direct measurements ofimportant dose
events (e.g., internal, delivered, or target
dose). Their value for exposure assessment,
however, also depends on whether they can
be used to reconstruct internal dose and
related exposures, and on whether they aid
in identifying and quantifying the relative
contributions ofvarious sources and path-
ways to exposure/dose.
If, for example, perfect data were avail-
able on biologically effective dose for a pop-
ulation of interest, identifying those
individuals at the upper end ofthe dose dis-
tribution would be straightforward. But in
the absence ofrelevant pharmacokinetic
information, extrapolating from biologi-
cally effective dose to delivered dose and
internal dose, and determining quantita-
tively the extent to which high (or low)
internal dose is correlated with high (or
low) exposure, are problematic. Thus,
despite the availability of"perfect" informa-
tion on target dose, it might still be neces-
sary to use a scenario approach to estimate
exposure and to determine important emis-
sion sources and exposure pathways.
Parenthetically, it is reasonable to ask
why, if "perfect" data on target dose were
on hand, wewould need to bother estimat-
ing exposure at all. The answer lies in the
realm ofrisk management.
Opportunities for intervention to pre-
vent or reduce unacceptable risks occur
almost exdusively in the ealier stages ofthe
environmental health paradigm (Figures
8,9). Effective and efficient risk manage-
ment strategies to protect public health
typically focus on intervening at key points
in the chain ofevents from source, to envi-
ronmental concentrations, to contact
between people and hazardous agents.
Therefore, it is critically important from a
risk management perspective to be able
quantitatively to link biologic markers to
exposure-related events (e.g., emissions,
concentrations in environmental media,
human time-activity and consumption
patterns) where public or private actions,
such as banning of harmful products,
installation of controls, and changes in
lifestyle, can reasonably be expected to
produce desired results.
In summary, the utility of measuring
biomarkers in human tissue for exposure
assessment depends on whether we can
interpret the significance ofthe biomarker
values for exposure, dose, and causes of
exposure/dose. Within this context, several
important questions related to the interpre-
tation ofbiomarkers need to be addressed
(43).
How are magnitude, duration, andfre-
quencyofexposure relatedto the biomarker?
* How soon after exposure will the bio-
marker appear?
* How soon after exposure will the bio-
marker reach its maximum value?
* How soon after exposure will the bio-
marker reach its steady-state value?
* How long will the biomarker persist
after exposure ends? (or alternatively,
howlong is its half-life?)
* What is the sensitivity and specificity
ofthe biomarker?
* What are the intraindividual, interindi-
vidual, and between-group variabilities
associated with the biomarker?
How is the marker related to the different
aspectsofdose?
* Is the marker a measure of internal,
delivered, or biologically effective dose?
* How is the marker related to other dose
events?
Isthe markerspecificfor
* Aparticular agent (e.g., lead)?
* A particular source (e.g., local
incinerator)?
* A particular source category (e.g.,
combustion sources)?
* A particular exposure setting (e.g.,
occupational)?
Failure to answer these and related
questions can seriously limit the role of
human tissue monitoring in exposure
assessment.
UsingBiomarkers to Improve
Exposure Estimates
Although the development and application
of biomarker measurements are still at a
relatively early stage, there is already ample
evidence showing their potential to
improve estimates ofexposure and dose.
An increasingly important use of
human monitoring data has been as a
"reality check" on indices of exposure
(e.g., questionnaires, work histories). The
evidence indicates that biomarkers are
invaluable for letting us evaluate whether
exposure indices accurately estimate and
classify people according to measured dose.
Needham et al. (45) presented case studies
Volume 103, Supplement3, April 1995 25SEXTONETAL.
Table 6. Case studies examining the relationship between exposure indices and human tissue measurements.
Correlation between
Postulated exposure Biomarker of delivered exposure index and
Study population Environmental agent(s) pathway/route Exposure index dose (body burden) measured dose
Members ofthe U.S. Air 2,3,7,8,-TCDD (dioxin) Direct contact Scenario evaluation Serum dioxin None
Force directly involved in based on average
spraying Agent Orange in concentration, and
Vietnam duration and frequency
of potential exposure
Members ofthe U.S. 2,3,7,8-TCDD Skin contactand inhala- Four indices based on Serum dioxin None
Army (ground troops) tion of spray; skin contact potential exposure to
potentially exposed to with sprayed vegetation direct spray orto areas
Agent Orange in Vietnam and soil; ingestion offood sprayed within six days,
and waterthat had been and two indices based on
sprayed self-reported data
Residents living near PCBs Skin contactwith contam- Residential proximity to Serum PCBs None
waste sites inated soil orwater, site
ingestion ofcontaminated
soil, water, orfish
Residents living down- DDT, and its metabolites Ingestion ofcontaminated Scenario evaluation Serum DDT, DDE, DDD Amountoffish eaten per
stream of defunct DDT DDE and DDD fish based on concentrations week significantly related
manufacturing plant in fish, and amount of to serum levels (age was
fish eaten perweek the best predictor)
Workers in plants that 2,3,7,8-TCDD Occupational exposures Scenario evaluation based Serum dioxin Serum dioxin levels were
produced chemicals by inhalation, ingestion, on duration of potential significantly related to
contaminated with dioxin or dermal contact exposure and reviewof the exposure index
occupational records
aFrom Needham et al.(45).
comparing exposure indices (e.g., a combi-
nation of environmental measurements
and questionnaire data) with measure-
ments ofdelivered dose (body burden). As
shown in Table 6, they found that there
was no correlation in three ofthe five cases.
They concluded that when indirect mea-
sures, such as questionnaires, concentra-
tions in environmental media, and
proximity to sources, are used to estimate
or classify exposures, it is important to
"validate and calibrate" the exposure index
against direct measurements of "internal
dose" in at least a subset ofthe potentially
exposed population.
Wallace et al. (46) measured levels of
25 volatile organic chemicals (VOCs) in
exhaled breath, "personal" air, and indoor
(residential) and outdoor air for a sample
of 50 people in the Los Angeles area of
California. They found that mean personal
air concentrations for almost all measured
VOCs were higher than indoor residential
air concentrations, which, in turn, were
much higher than matched outdoor values.
Exhaled breath samples were significantly
correlated with "personal" air measure-
ments for the preceeding 12 hr for most
VOCs. Chloroform and limonene, VOCs
that did not exhibit good breath-to-air
correlations, have other important routes
ofexposure: chloroform has dietary expo-
sures from tap water, cold beverages, and
dairy products; and limonene has dietary
exposures from foods and beverages.
According to their findings, VOCs in
breath can provide direct evidence ofexpo-
sure and dose across multiple routes, and
breath measurements can make a valuable
contribution to studies ofVOC exposure.
Pirkle et al. (47) pointed out that the
classic example of a biomarker that
improves exposure estimates is lead in
blood ("blood lead"). The accuracy and
precision ofblood lead measurements have
improved greatly over the past 15 years,
while costs have decreased. During that
time, blood lead has become the standard
dose metric, allowing for direct comparison
oflead doses across different studies. This
ability to combine multiple studies was
instrumental in development ofepidemio-
logic evidence that led to the decision by
the Centers for Disease Control and
Prevention (CDC) to lower the action
threshold from a blood lead level of 25
pg/dl to 10 pg/dl (47).
The decision to phase out lead in gaso-
line presents a dramatic illustration of the
value of blood lead as a biomarker of
exposure. Prior to the decision, exposure
models suggested that eliminating lead in
gasoline would have a slight effect on
blood lead levels (47). However, as shown
in Figure 11, data from the second
National Health and Nutrition Exami-
nation Survey (NHANES II) revealed that
as lead in gasoline decreased (about 55%)
from 1976 to 1980 when unleaded fuel
was introduced, there was a parallel
decrease (about 37%) in mean blood lead
levels in the United States population
(from approximately 16 pg/dl to less than
10 pg/dl) (47,48). These data were
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Figure 11. Observed decreases in the amount of lead
used in gasoline in the United States and parallel
decreases in blood lead values measured as part of
NHANES II from 1976 to 1980 (48).
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"a dominant factor" in the U.S. EPA's
decision to implement a phase out of
leaded gasoline (47).
Need for Baseline Data on
Exposure and Dose
The evidence continues to mount that esti-
mates of exposure can be improved sub-
stantially by using a combination of
exposure measurements and dose measure-
ments. Still, owing to resource constraints,
relatively few studies have been conducted
using this combined approach. Those that
have been done are mostly small-scale,
pilot-type investigations that have not
employed rigorous, population-based,
probability sampling techniques. Conse-
quently, determining whether and to what
extent exposure measurements and bio-
marker measurements are representative of
people and situations beyond the original
study is problematic.
With few exceptions, such as data on
blood lead, there are inadequate and insuf-
ficient data to describe the exposure and
dose distribution for the "general" popula-
tion, as well as for those potentially at
greater risk (i.e., more exposed, more sus-
ceptible, or both). It is generally not possi-
ble, therefore, to put measurements of
either exposure or dose into context.
That is to say, we do not have a good
understanding ofwhere the measured val-
ues fall on the local, regional, or national
distribution ofexposure and dose.
Such knowledge is essential ifwe are to
make informed decisions about potential
environmental hazards. This is especially
true in the face of intense media pressure
or public outrage. In retrospect, had the
scientific information and knowledge been
available to let us immediately place the
monitoring data from Love Canal, New
York and Times Beach, Missouri into
proper perspective, both the communities
and the government might have reacted
differently.
There is an obvious and acute need for a
national monitoring program to define the
distribution ofexposure and dose and to
document status and trends for the United
States population. Among those who have
called for such a surveillance effort are the
National Research Council (NRC) (2-5),
several members ofCongress (49,50), the
Environmental Defense Fund (51), the
U.S. EPA's Science Advisory Board
(52,53), and a broad spectrum ofthe sci-
entific community (10,11,15-17). The
reasons that measurements of biomarkers
must be an integral part ofsuch a program
have been summarized by the NRC (4):
* Tissue samples reflect exposures
accumulated over time.
* Tissue samples reflect exposures by all
routes, including some that are difficult
or impossible to assess by environmen-
tal measurement (such as hand-to-
mouth ingestion in young children).
* Pollutants in tissue samples have
undergone the modifying effects of
physiology and biologic availability.
* Some agents are more concentrated,
and so more readily detectable, in tissue
samples than in the environment.
* Tissue samples offer the opportunity to
correlate, within a given person, the tis-
sue concentration of toxicants with
other tissue-based biologic markers or
indicators of effect that might be
predictive ofinjury or disease.
The NRC goes on to say, "All these
characteristics, taken together, make tissue
monitoring as an assessment tool an
important adjunct to environmental moni-
toring that is uniquely valuable in indicat-
ing both exposures and doses that lead to
potentiallyharmful effects" (4).
Changes in Nature and
Scope of Risk Assessments
There are indications that the nature and
scope ofrisk assessments are expanding in
important ways, which may have signifi-
cant ramifications for the role of human
tissue monitoring in exposure assessment.
Risks other than cancer, including adverse
effects on reproduction, development, the
nervous system, pulmonary and cardiovas-
cular function, and the immune system,
are becoming more important in regulatory
and policy decisions. In addition to life-
time exposures, concerns increasingly focus
on a wide variety of shorter term expo-
sures: exposures from accidental or emer-
gency releases of hazardous materials
(hours or days); peak air pollution expo-
sures during stagnant meteorological con-
ditions (hours or days); peak waterborne
exposures caused by runoff from agricul-
tural activities (hours or days); exposures to
pregnant women and fetuses during critical
developmental periods (minutes or hours);
and exposures of "sensitive" individuals
(e.g., allergic, hypersensitive) to brief con-
tact with environmental agents (minutes,
hours, or days).
The scope of risk assessment is also
broadening from a narrow focus on incre-
mental risks associated with individual
environmental agents and single exposure
pathways. Now the emphasis is often on
understanding "total" exposure for
an individual or population from all
important sources, pathways, and routes of
exposure, either for a specific agent or
mixture ofagents. For example, instead of
looking only at incremental risks related to
air pollution emissions from a particular
source, assessors are beginning to examine
comparative and cumulative risks for the
population of a defined geographic area
from all important sources, via all
important pathways.
These and related changes in risk assess-
ment are being driven by a move toward
more comprehensive management ofenvi-
ronmental health risks. The magnitude and
extent of environmental health problems,
the associated costs of mitigation and
remediation, and the need to balance the
nation's budget are forcing hard societal
decisions about strategic directions and
how resources will be allocated among
competing needs. A broad-based consensus
seems to be emerging that "risk-based pri-
ority setting" is the method of choice to
ensure that scarce resources are used to
address the "worst" problems first. In
essence, risk-based priority setting com-
pares and ranks health risks (both cancer
and noncancer), as well as other types of
risks (e.g., welfare, ecologic), to establish
priorities for resource allocation (24).
This "comparative" risk approach
focuses attention on the components of
"total" environmental health risk for peo-
ple in a defined geographic area, such as a
metropolitian center, state, region, or the
entire country. To achieve its goal ofiden-
tifying the worst comparative risks, risk-
based priority setting requires data or
informed estimates of total exposures for
the population of interest. Thus, it creates
an immediate need for exposure assess-
ments that are qualitatively different from
those traditionally conducted.
In the context oftotal exposure assess-
ments, scenario construction alone
becomes a less viable option because ofthe
difficulties in identifying, let alone quanti-
fying the relative contributions of all
important exposure pathways. Further-
more, measurement of relevant exposure
concentrations remains problematic due to
the technical infeasibility ofcost-effectively
monitoring for all agents of interest (e.g.,
pesticides, metals, microorganisms,
radionuclides), in all environmental media
(e.g., air, beverages, food, surfaces), for all
applicable settings (e.g., occupational,
residential, transportational). In many
instances, reconstructive exposure assess-
ment, based on measurement ofbiologic
markers ofexposure in human tissues and
excreta, is a necessary addition to exposure
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assessment methodology for realistic
estimation of total exposures for the
population ofinterest.
Summary and Conclusions
Realistic assessment ofhealth risks associ-
ated with exposures to environmental
agents depends on adequate knowledge and
understanding ofboth exposures and their
associated effects. Within the risk assess-
ment framework, exposure assessment is a
formalized process, subject to explicit
guidelines, that attempts to estimate the
number ofpeople exposed to specific con-
centrations of the agent for the period of
interest, the resulting dose, and the contri-
bution ofimportant sources and pathways
to exposure and dose. Because direct mea-
surements ofexposure and dose are scarce,
and because of the narrow focus of the
questions being asked, most assessments
historically have been conducted by
constructing exposure scenarios.
Theoretically, concentrations ofenvi-
ronmental agents or their metabolites/
derivatives measured in human tissues and
excreta can be used to "reconstruct" inter-
nal dose. Ifthis information is then com-
bined with intake and uptake rates, it is
possible to calculate associated exposures.
In practice, "reconstructive exposure assess-
ment" is seldom used because we lack
appropriate pharmacokinetic information
to link biomarker measurements to expo-
sure. However, continuing scientific and
technological advances in the measurement
and understanding ofbiomarkers, as well as
changes in the nature and scope of risk
assessments, indicate that this approach has
significant potential to improve the realism
ofexposure assessments.
It is important to remember, however,
that direct measurements ofexposure and
measurements of dose are not substitutes
for each other. They are complementary
rather than competing methods for con-
ducting realistic exposure assessments. The
most scientifically credible risk characteri-
zations will employ a combination ofboth
types of evidence. Ultimately, whether
measurements ofbiomarkers strengthen,
and perhaps "revolutionize," exposure
assessments depends on the extent to which
we achieve a better understanding of the
interrelationships among exposure path-
ways, exposure concentrations, and related
dose.
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